A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02)

ABSTRACT: Interventions: Patients receive infusional oxaliplatin, bevacizumab, and oral TS-1 every 21 days. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced/metastatic Colorectal Cancer

PROVIDER: 2620419 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR